Long-Term Safety from the Raltegravir Clinical Development Program

By  

Current HIV Research, Vol. 9, Iss. 1, 2011-01 ,pp. : 40-53

Bentham Science Publishers

Access to resources Recommend Favorite

Differential regulation of GHRH-receptor and GHS-receptor expression by long-term in vitro treatment of ovine pituitary cells with GHRP-2 and GHRH

By Roh Sang-Gun   Doconto Maria   Feng Dan   Chen Chen  

Endocrine Journal, Vol. 30, Iss. 1, 2006-08 ,pp. : 55-62

Humana Press, Inc

Access to resources Recommend Favorite

The Human Epidermal Antimicrobial Barrier: Current Knowledge, Clinical Relevance and Therapeutic Implications

By  

Recent Patents on Anti-Infective Drug Discovery, Vol. 10, Iss. 2, 2015-08 ,pp. : 84-97

Bentham Science Publishers

Access to resources Recommend Favorite

Recombinant Human Factor X - A two-component therapeutic for the treatment of coagulopathies particularly hemophilia with inhibitor

By Himmelspach M.   Pfleiderer M.   Fischer B.E.   Plaimauer B.   Antoine G.   Falkner F.G.   Dorner F.   Schlokat U.  

Thrombosis Research, Vol. 97, Iss. 2, 2000-01 ,pp. : 51-67

Elsevier

Access to resources Recommend Favorite

Growth hormone/insulin-like growth factor1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1–44 NH₂ and in combination in older men and women with decreased growth hormone secretion

By Bowers C.   Granda-Ayala R.  

Endocrine Journal, Vol. 14, Iss. 1, 2001-02 ,pp. : 79-86

Humana Press, Inc

Access to resources Recommend Favorite